ReviewCurrent opinion in pharmacology2016
Integrating structural and mutagenesis data to elucidate GPCR ligand binding.
Review in Current opinion in pharmacology, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 32 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
32 citing papers in PubMed.
- An online GPCR drug discovery resource.npj drug discovery · 2025Article
- Generic residue numbering of the GAIN domain of adhesion GPCRs.Nature communications · 2025Article
- ProteinReDiff: Complex-based ligand-binding proteins redesign by equivariant diffusion-based generative models.Structural dynamics (Melville, N.Y.) · 2024Article
- Computer-Aided Drug Design and Drug Discovery: A Prospective Analysis.Pharmaceuticals (Basel, Switzerland) · 2023Review
- SH2db, an information system for the SH2 domain.Nucleic acids research · 2023Article
- GPCRdb in 2023: state-specific structure models using AlphaFold2 and new ligand resources.Nucleic acids research · 2023Article
- Opportunities and Challenges for In Silico Drug Discovery at Delta Opioid Receptors.Pharmaceuticals (Basel, Switzerland) · 2022Review
- Covalent cannabinoid receptor ligands - structural insight and selectivity challenges.RSC medicinal chemistry · 2022Review
- The pocketome of G-protein-coupled receptors reveals previously untargeted allosteric sites.Nature communications · 2022Article
- The G protein database, GproteinDb.Nucleic acids research · 2022Article
- Allosteric Effect of Nanobody Binding on Ligand-Specific Active States of the β2 Adrenergic Receptor.Journal of chemical information and modeling · 2021Article
- An online GPCR structure analysis platform.Nature structural & molecular biology · 2021Article
- Bitter Taste and Olfactory Receptors: Beyond Chemical Sensing in the Tongue and the Nose.The Journal of membrane biology · 2021Article
- PyPLIF HIPPOS-Assisted Prediction of Molecular Determinants of Ligand Binding to Receptors.Molecules (Basel, Switzerland) · 2021Article
- Understanding the influence of lipid bilayers and ligand molecules in determining the conformational dynamics of somatostatin receptor 2.Scientific reports · 2021Article
- GPCRdb in 2021: integrating GPCR sequence, structure and function.Nucleic acids research · 2021Article
- Variation in the Evolution and Sequences of Proglucagon and the Receptors for Proglucagon-Derived Peptides in Mammals.Frontiers in endocrinology · 2021Article
- Molecular-Level Understanding of the Somatostatin Receptor 1 (SSTR1)-Ligand Binding: A Structural Biology Study Based on Computational Methods.ACS omega · 2020Article
- GPCRmd uncovers the dynamics of the 3D-GPCRome.Nature methods · 2020Article
- Dual binding mode of "bitter sugars" to their human bitter taste receptor target.Scientific reports · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
G protein-coupled receptors (GPCRs) represent the largest family of human membrane proteins, as well as drug targets. A recent boom in GPCR structural biology has provided detailed images of receptor ligand binding sites and interactions on the molecular level. An ever-increasing number of ligands is reported that exhibit activity through multiple receptors, binding in allosteric sites, and bias towards different intracellular signalling pathways. Furthermore, a wealth of single point mutants has accumulated in literature and public databases. Integrating these structural and mutagenesis data will help elucidate new GPCR ligand binding sites, and ultimately design drugs with tailored pharmacological activity.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.